Institute of Nutraceuticals and Functional Foods (INAF), 2440 Hochelaga Boulevard, Laval University, Quebec City, Quebec, Canada.
Int J Food Microbiol. 2011 Sep 1;149(1):50-7. doi: 10.1016/j.ijfoodmicro.2010.12.026. Epub 2011 Jan 15.
This randomized, placebo-controlled, double blind, parallel dose-response study investigated the impact of 4-week commercial yoghurt consumption supplemented with Bifidobacterium animalis subsp. lactis (BB-12) and Lactobacillus acidophilus (LA-5) on fecal bacterial counts of healthy adults. Fifty-eight volunteers were randomly assigned to three different groups: 1. placebo (no probiotic, no starter and no green tea extract); 2. Yoptimal (10(9)cfu/100g of BB-12 and LA-5 and 40mg of green tea extract) and 3. Yoptimal-10 (10(10)cfu/100g of BB-12, 10(9)cfu/100g of LA-5 and 40mg of green tea extract). These yoghurt products also contained Lactobacillus delbrueckii subsp. bulgaricus (10(7)cfu/100g) and Streptococcus thermophilus (10(10)cfu/100g). The quantitative PCR (qPCR) results showed that there were significant increases (P=0.02) in bifidobacteria counts with the Yoptimal treatment as compared to baseline. The fecal numbers of B. animalis subsp. lactis and LA-5 significantly increased in the two probiotic treatments compared to the placebo treatment. Viable counts of fecal lactobacilli were significantly higher (P=0.05) and those of enterococci were significantly lower (P=0.04) after the intervention when compared to placebo. No significant difference was observed between treatments in volunteers' weight, waist girth, blood pressure, fasting plasma triglyceride and HDL-C concentrations, as well as cholesterol/HDL-cholesterol ratio. However, a significant increase in plasma cholesterol levels was observed in the placebo group (P=0.0018) but the levels remained stable in the two probiotic yoghurt groups. These results show that probiotic strains supplemented in the form of yoghurt remain active during gut transit and are associated with an increase in beneficial bacteria and a reduction in potentially pathogenic bacteria. This trial was registered at clinicaltrials.gov as NCT00730626.
这项随机、安慰剂对照、双盲、平行剂量反应研究调查了 4 周商业酸奶消费补充双歧杆菌动物亚种。乳杆菌（BB-12）和嗜酸乳杆菌（LA-5）对健康成年人粪便细菌计数的影响。58 名志愿者被随机分配到三个不同的组：1. 安慰剂（无益生菌、无启动子和无绿茶提取物）；2. Yoptimal（10（9）cfu/100g 的 BB-12 和 LA-5 和 40mg 绿茶提取物）和 3. Yoptimal-10（10（10）cfu/100g 的 BB-12、10（9）cfu/100g 的 LA-5 和 40mg 绿茶提取物）。这些酸奶产品还含有德氏乳杆菌保加利亚亚种（10（7）cfu/100g）和嗜热链球菌（10（10）cfu/100g）。定量 PCR（qPCR）结果表明，与基线相比，Yoptimal 处理组双歧杆菌计数有显著增加（P=0.02）。与安慰剂组相比，两种益生菌治疗组粪便中乳双歧杆菌和 LA-5 的数量明显增加。与安慰剂相比，干预后粪便乳酸菌的活菌数显著升高（P=0.05），肠球菌的活菌数显著降低（P=0.04）。志愿者体重、腰围、血压、空腹血浆甘油三酯和高密度脂蛋白胆固醇浓度以及胆固醇/高密度脂蛋白胆固醇比值在治疗组之间无显著差异。然而，安慰剂组血浆胆固醇水平显著升高（P=0.0018），而两种益生菌酸奶组的水平保持稳定。这些结果表明，以酸奶形式补充的益生菌菌株在肠道转运过程中保持活性，并与有益细菌的增加和潜在致病细菌的减少相关。该试验在 clinicaltrials.gov 上注册为 NCT00730626。
